Weam Aldiban: The Critical Impact of Pharmacogenetic Variation on Dabigatran Exposure and Bleeding Risk
Weam Aldiban, Head of Pharmacology & Toxicology Department at IUST University, shared a post on LinkedIn:
“Excited to share our latest publication in Human Genomics!
Title: The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis
Our study highlights the critical impact of pharmacogenetic variation on dabigatran exposure and bleeding risk. Key findings include:
– ABCB1 rs/148738 CT/TT genotypes → lower trough concentrations
– CES1 rs8192935 GG genotype → increased peak concentrations
– CES1 rs2244613 TT genotype → elevated peak/trough levels and bleeding risk
– CES1 rs2244613 GT genotype → increased trough levels only
These insights underscore the importance of personalized medicine in anticoagulant therapy and call for large-scale prospective studies across diverse populations to validate and expand upon our findings.
Grateful to our team and collaborators for their dedication and rigor. Let’s keep pushing the boundaries of precision pharmacotherapy!”
Title: The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis
Authors: Weam Aldiban, Nada G. Hamam, Nereen A. Almosilhy, Kholoud Elsamman, Mohamed Wagdy, Doaa Mashaly, Suhel F. Batarseh, Youssef El-Sherif, Basma Badrawy Khalefa, Zina Otmani
Read full paper here.
Stay informed with Hemostasis Today.
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals